Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Ambrx Biopharma (AMAM) News Today

Ambrx Biopharma logo

AMAM Latest News

14 Day AMERIBOR Average Rate (^AMBRX)
Johnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash Deal
3 Stocks to Buy That Are Up 200% or More in 2024
Ambrx Biopharma just downgraded at JMP Securities, here's why
Ambrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&J
Johnson & Johnson: Biotech a shot in the arm for future growth?
Johnson & Johnson: Biotech a shot in the arm for future growth? (AMAM)
Johnson & Johnson is actively shifting its strategy towards biotechnology and antibody-drug conjugates, balancing current revenue protection with future growth.
Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
Ambrx Announces Sale to Johnson & Johnson
Ambrix to Join NASDAQ Biotech Index
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
Optimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy Rating
Goldman Sachs Keeps Their Hold Rating on Ambrx Biopharma (AMAM)
Analyst Ratings for Ambrx Biopharma
Get Ambrx Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter.

AMAM Media Mentions By Week

AMAM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AMAM
News Sentiment

0.00

0.90

Average
Medical
News Sentiment

AMAM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AMAM Articles
This Week

0

0

AMAM Articles
Average Week

Get Ambrx Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NYSE:AMAM) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners